

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

**Complete if Known**

Application Number	10/806,295
Filing Date	March 22, 2004
First Named Inventor	LaColla, <i>et al.</i>
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	06171.105033 IDX 1008 DIV

3463446 2.DOC

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
Gm	AA	4,866,084	A	Gunasekera <i>et al.</i>	09-12-1989	
	AB	5,124,327	A	Greenlee <i>et al.</i>	06-23-1992	
	AC	5,489,685	A	Houpis <i>et al.</i>	02-06-1996	
	AD	5,527,819	A	Williams <i>et al.</i>	06-18-1996	
	AE	5,830,894	A	Pevear <i>et al.</i>	11-03-1998	
	AF	5,852,011	A	Matsunaga <i>et al.</i>	12-22-1998	
	AG	5,929,114	A	Domagala <i>et al.</i>	07-27-1999	
	AH	5,935,982	A	Dykstra <i>et al.</i>	08-10-1999	
	AI	5,945,440	A	Kleinschroth <i>et al.</i>	08-31-1999	
	AJ	5,981,525	A	Farina <i>et al.</i>	11-09-1999	
	AK	6,025,390	A	Farina <i>et al.</i>	02-15-2000	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
Gm	AL	EP	0,530,907	A1	Merck & Co.	03-10-1993		
	AM	WO	94/19321	A1	Merck & Co., Theoharides	09-01-1994		
Gm	AN	WO	02/083126	A1	Idenix; Univ. Degli Studi di Cagliari	10-24-2002		
Gm	AO	WO	04/014364	A1	Idenix	02-19-2004		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
Gm	AP	BALANI, S.K., <i>et al.</i> , "Biotransformation of 5-chloro-3-phenylthioindole-2-carboxamide (L-734,005) in rhesus monkeys and rat liver microsomes to a potent HIV-1 reverse transcriptase inhibitor," <i>Drug Metab. Dispos.</i> , 21(4):598-604 (July-August 1993).	


Examiner  
SignatureDate  
Considered

10/28/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitution form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

Application Number	10/806,295
Filing Date	March 22, 2004
First Named Inventor	LaColla, <i>et al.</i>
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	06171.105033 IDX 1008 DIV

3463446 2.DOC

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	<del>AQ</del>	<del>CLAUSON-KAAS, N., <i>et al.</i>, "Preparation of <i>Cis</i> and <i>Trans</i> 2,5-Dimethoxy-2-(acetamidomethyl)-2,5-dihydrofuran, of <i>Cis</i> and <i>Trans</i> 2,5-Dimethoxy-2-(acetamidomethyl)-tetrahydrofuran and of 1-Phenyl-2-(acetamidomethyl)pyrrole," <i>Acta Chem. Scand.</i>, 6:667-670 (1952).</del>	
	<del>BA</del>	<del>ELMING, N., <i>et al.</i>, "The preparation of pyrroles from furans," <i>Acta Chem. Scand.</i>, 6:867-874 (1952).</del>	
	<del>BB</del>	<del>GAGLIARDI, S., <i>et al.</i>, "5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H<sup>+</sup>-ATPase of osteoclasts with bone antiresorptive activity," <i>J. Med. Chem.</i>, 41(10):1568-1573 (May 7, 1998).</del>	
	<del>BC</del>	<del>PAUWELS, R., <i>et al.</i>, "Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives," <i>Nature</i>, 343(6257):470-474 (February 1, 1990).</del>	
	<del>BD</del>	<del>PAUWELS, R., <i>et al.</i>, "Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase," <i>Proc. Natl. Acad. Sci. USA</i>, 90(5):1711-1715 (March 1, 1993).</del>	
	<del>BE</del>	<del>PHILLIPS, R.R., "The Japp-Klingemann Reaction," <i>Org. Reactions</i>, 10:143-178 (1959).</del>	
	<del>BF</del>	<del>ROMERO, D.L., <i>et al.</i>, "Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate," <i>J. Med. Chem.</i>, 36(10):1505-1508 (May 14, 1993).</del>	
	<del>BG</del>	<del>WILLIAMS, T.M., <i>et al.</i>, "5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase, <i>J. Med. Chem.</i>, 36(9):1291-1294 (April 30, 1993).</del>	

Examiner  
SignatureDate  
Considered

10/28/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.